Drug Repurposing and Discovery of New Kinase Inhibitors as Potential Drug Candidates
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 November 2022)
Special Issue Editor
Interests: heterocycle synthesis; drug design and repurposing; anticancer agents; kinase inhibitors; small molecules, bioactive compounds; in silico evaluation; biological activity
Special Issue Information
Dear Colleagues,
Protein kinases (PKs) are critical for target identification in drug therapy for cancer and autoimmune diseases, among many others. PKs are enzymes that selectively modify substrates by adding a phosphate group in a process called phosphorylation. As PKs greatly affect cell biology, their activity is highly regulated, and any loss of control can lead to abnormal cell behavior, and in some cases, disease development, such as cancer. Among the 52 FDA-approved drugs known to act against kinase proteins, at least 21 are considered multikinase inhibitors. Moreover, there are currently more than 220 different compounds undergoing clinical trials worldwide with potential for use in several diseases. Kinase inhibitors have had a significant impact on the way in which we treat cancers and noncancerous conditions. This Special Issue will provide an overview of the latest advances in the field of drug repurposing and kinase inhibitors and their applications in a diverse range of areas.
Selected contributions on advances in the synthesis, characterization, and medical potential applications of kinase inhibitors will be presented.
Potential topics include, but are not limited to:
Heterocycle synthesis for kinase inhibition;
Drug design and repurposing of small molecules as potential kinase inhibitors;
Drug discovery and repurposing of small molecules as kinase inhibitory leads;
Kinase inhibitors as anticancer agents;
Molecular docking and computer-aided design of anticancer agents with kinase inhibitory MOA;
In silico and in vitro biological evaluation of new compounds able to inhibit protein kinase(s).
Dr. Ahmed Elkamhawy
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heterocycle synthesis
- drug design and repurposing
- anticancer agents
- kinase inhibitors
- small molecules
- bioactive compounds
- in silico evaluation
- biological activity
